J
James K. Weick
Researcher at Cleveland Clinic
Publications - 67
Citations - 4166
James K. Weick is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Chemotherapy & Vincristine. The author has an hindex of 29, co-authored 66 publications receiving 4103 citations. Previous affiliations of James K. Weick include Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
Kathy S. Albain,Valerie W. Rusch,John Crowley,Thomas W. Rice,Andrew T. Turrisi,James K. Weick,Vassyl A. Lonchyna,Cary A. Presant,Robert McKenna,David R. Gandara,Helen Fosmire,Sarah A. Taylor,Keith J. Stelzer,Kristen R. Beasley,Robert B. Livingston +14 more
TL;DR: The strongest predictor of long-term survival after thoracotomy was absence of tumor in the mediastinal nodes at surgery, and this trimodality approach was feasible in this Southwest Oncology Group (SWOG) study.
Journal ArticleDOI
Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study
Catherine P. Leith,Kenneth J. Kopecky,I-Ming Chen,Lisette Eijdems,Marilyn L. Slovak,Thomas S. McConnell,David R. Head,James K. Weick,Michael R. Grever,Frederick R. Appelbaum,Cheryl L. Willman +10 more
TL;DR: MDR1 is less frequent in younger AML patients, which may in part explain their better response to therapy and neither MRP1 nor LRP are significant predictors of outcome in this patient group, so inclusion of MDR1-modulators alone may benefit younger AMl patients with MDR 1(+) disease.
Journal ArticleDOI
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
James K. Weick,Kenneth J. Kopecky,Frederick R. Appelbaum,David R. Head,Laura Kingsbury,Stanley P. Balcerzak,John N. Bickers,H. E. Hynes,Jeanna L Welborn,Sheryl R. Simon,Michael R. Grever +10 more
TL;DR: Patients who received both HDAC induction and consolidation had the best postremission outcomes; however, the proportion of CR patients who did not go on to protocol consolidation therapy was more than twice as high afterHDAC induction compared with SDAC.
Journal ArticleDOI
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Jane N. Winter,Edie Weller,Sandra J. Horning,Maryla Krajewska,Daina Variakojis,Thomas M. Habermann,Richard I. Fisher,Paul J. Kurtin,William R. Macon,Mukesh Chhanabhai,Raymond E. Felgar,Eric D. Hsi,L. Jeffrey Medeiros,James K. Weick,John C. Reed,Randy D. Gascoyne +15 more
TL;DR: A reduction in treatment failures and death with the addition of R to CHOP in Bcl-6(-) DLBCL cases only is observed, and the finding that Bcl(+) cases did not benefit from the additionof R toCHOP requires independent confirmation.
Journal ArticleDOI
N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance
Jerald P. Radich,Kenneth J. Kopecky,Cheryl L. Willman,James K. Weick,David R. Head,Frederick R. Appelbaum,Steven J. Collins +6 more
TL;DR: A comparison of patients with and without N-ras mutations showed no statistically significant differences in pretreatment clinical variables, response to induction therapy, or survival, except for a possibly higher percentage of FAB M4 subtypes in patients with the N-ra mutation.